Letter to the Editor
Sir: The new antidepressant mirtazapine (Remeron) has a
unique mode of action, combining an increase of noradrenergic
and 5-HT1A-mediated serotonergic neurotransmission with a
specific blockade of 5-HT2 and 5-HT3-receptor subtypes. So
far, a single case of overdose with mirtazapine has been reported
since its introduction in The Netherlands in September
1994; I now report the second case.
Author Affiliations
Save
Share
Cite
